(Finance) – Record yourselfa multinational pharmaceutical company that is part of the FTSE MIB, and its main shareholder CVC Capital Partners they state that “there is no dialogue and we do not expect there will be any dialogue in the future neither with the management nor with the shareholders of Angelini Pharma” regarding a potential merger between Recordati and Angelini Pharma.
This morning Il Sole 24 Ore he wrote that large sovereign funds and some of the largest international pension funds are evaluating the dossier of the marriage between Recordati and Angelini, but the road to finding an agreement is uphill. According to the newspaper, the Angelini family would be willing to transfer their activities in the pharmaceutical sector to a new company and then merge them with Recordati, but the operation would require a robust injection of cash and for this reason private equity funds would have been contacted.
CVC confirms that it is not contemplating any transaction with Angelini Pharma or its shareholders, e categorically denies the title of the article who says he is “waiting for a proposal,” the note reads.
Furthermore, it is emphasized that none of the banks who work for CVC or Recordati mentioned in the article are working on the alleged merger. The article mentioned Rothschild, Morgan Stanley, Barclays, Goldman Sachs And JPMorgan.